MAP2K7 and cancer: Growth arrest and suppression of survival oncogenic drivers by hyper-activated Erk may offer a treatment mode for mutated B-Raf cancers, that avoids the frustrating chase after individual resistant targets that dynamically evolve upon suppressing B-Raf(V600E)/MEK/MAPK by kinase inhibitors.